Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort

Publisher： John Wiley & Sons Inc

E-ISSN： 1445-5994|45|10|1054-1065

ISSN： 1444-0903

Source： INTERNAL MEDICINE JOURNAL, Vol.45, Iss.10, 2015-10, pp. : 1054-1065

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission

By  

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 181, Iss. 2, 2015-08 ,pp. : 306-313

John Wiley & Sons Inc

Access to resources Recommend Favorite

Haemolytic Uraemic Syndrome

By  

Nephron Clin Pract, Vol. 118, Iss. 1, 2010-11 ,pp. : c37-c42

Karger

Access to resources Recommend Favorite

Living‐donor kidney transplantation for atypical haemolytic uremic syndrome with pre‐emptive eculizumab use

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 3, 2015-03 ,pp. : 366-369

John Wiley & Sons Inc

Access to resources Recommend Favorite

Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome

By  

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 181, Iss. 1, 2015-07 ,pp. : 118-125

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 3, 2015-03 ,pp. : 485-486

John Wiley & Sons Inc

Access to resources Recommend Favorite